A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
Sponsor: |
Gilead |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS9654 |
U.S. Govt. ID: |
NCT04292730 |
Contact: |
Allison Wolf: 212-342-4412 / aw2565@cumc.columbia.edu |
There are no approved medications to treat COVID-19, a new disease caused by a virus called SARS-CoV-2 that was just identified in late 2019. Some people who become sick with COVID-19 develop a very serious disease. The purpose of this study is to see if Remdesivir (RDV) can improve your health from being sick with COVID-19 infection. The other purpose of this study is to test if RDV is safe and tolerated by people with moderate COVID-19. We will find out all these things, and also how long it stays in your body, using physical exams, laboratory tests, and any symptoms or problems you might experience during the study.
This study is closed
Investigator
Max O'Donnell, MD, MPH
Is the patient 12 years of age or older? |
Yes |
No |
Has the patient tested positive for COVID-19? |
Yes |
No |
Is the patient currently hospitalized and requiring medical care for COVID-19? |
Yes |
No |
Does the patient currently require mechanical ventilation? |
Yes |
No |